Zai Lab (NASDAQ:ZLAB) Posts Quarterly Earnings Results, Beats Estimates By $0.22 EPS

Zai Lab (NASDAQ:ZLAB) released its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.22, Zacks reports. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The firm had revenue of $106.31 million during the quarter, compared to the consensus estimate of $103.87 million.

Here are the key takeaways from Zai Lab’s conference call:

• Positive Sentiment: Zai Lab reported second-quarter net product revenue of $105.8 million, up 11% sequentially, while maintaining a commercially profitable business. Management expects KarXT, potential NRDL inclusions, and continued demand for key brands to support meaningful growth in 2027.
• Positive Sentiment: The DLL3 ADC zoci is advancing rapidly, with a global Phase III second-line small-cell lung cancer trial expected to complete enrollment in the first half of 2027 and a potential U.S. accelerated-approval submission later that year. The company also plans a first-line, chemo-sparing Phase III combination study and expects three registrational programs by year-end.
• Positive Sentiment: ZL-1503, a long-acting IL-13/IL-31 bispecific for atopic dermatitis, is expected to generate initial human pharmacokinetic, pharmacodynamic, safety, and immunogenicity data in the second half of 2026. Zai believes its potential for durable itch reduction, skin clearance, and less frequent dosing could differentiate it in a competitive market.
• Negative Sentiment: Management did not reaffirm its prior goal of reaching overall profitability by the end of 2025, instead indicating that profitability will develop over time as revenue grows and global assets advance. Continued investment in multiple global programs means operating expenses are expected to remain broadly stable through the rest of 2026.
• Neutral Sentiment: The company ended the quarter with $717.5 million in cash and is prioritizing spending on its highest-value programs while streamlining operations and expanding AI use across functions. Additional pipeline catalysts include initial ZL-6201 data expected in the first half of 2027 and an IND filing for the MUC17 T-cell engager ZL-1311 by year-end.

Zai Lab Trading Up 13.7%

NASDAQ:ZLAB opened at $20.88 on Friday. The company has a market cap of $2.38 billion, a PE ratio of -12.89 and a beta of 0.78. Zai Lab has a twelve month low of $15.96 and a twelve month high of $36.77. The company’s 50 day moving average is $18.64 and its two-hundred day moving average is $19.22.

Insider Buying and Selling at Zai Lab

In other news, CEO Ying Du sold 50,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $20.09, for a total transaction of $1,004,500.00. Following the sale, the chief executive officer directly owned 1,122,626 shares of the company’s stock, valued at $22,553,556.34. The trade was a 4.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Lis sold 7,040 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $18.09, for a total value of $127,353.60. Following the completion of the transaction, the director directly owned 50,437 shares in the company, valued at approximately $912,405.33. The trade was a 12.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 90,873 shares of company stock worth $1,730,096. 4.88% of the stock is owned by corporate insiders.

Institutional Trading of Zai Lab

An institutional investor recently raised its stake in Zai Lab stock. Royal Bank of Canada grew its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. Institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ZLAB. Citigroup cut their target price on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wall Street Zen cut shares of Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Zacks Research upgraded shares of Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.